| Suspended | Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing He NCT06968195 | Roswell Park Cancer Institute | Phase 1 |
| Not Yet Recruiting | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tum NCT07405086 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer NCT07174570 | Emory University | Phase 2 |
| Recruiting | Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combinatio NCT07227012 | Pfizer | Phase 1 / Phase 2 |
| Recruiting | Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) NCT06811116 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing NCT06066138 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tu NCT06915753 | Tyra Biosciences, Inc | Phase 1 |
| Recruiting | A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma NCT06600321 | Alnylam Pharmaceuticals | Phase 1 |
| Recruiting | A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Partic NCT06427941 | BeOne Medicines | Phase 1 |
| Withdrawn | A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic NCT06006286 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezoliz NCT05199285 | Academic and Community Cancer Research United | Phase 2 |
| Recruiting | Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, NCT05168163 | Academic and Community Cancer Research United | Phase 2 |
| Recruiting | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Pa NCT05092373 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Recruiting | GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies NCT05003895 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide NCT05075993 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liv NCT04828486 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subj NCT03937830 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment NCT04511455 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Completed | Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hep NCT04401800 | BeiGene | Phase 2 |
| Recruiting | Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers NCT04221893 | University of California, San Francisco | N/A |
| Active Not Recruiting | Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver NCT04175912 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral NCT04025567 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) NCT03893695 | Suzhou Kintor Pharmaceutical Inc, | Phase 1 / Phase 2 |
| Terminated | BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer NCT03695250 | Edward Kim | Phase 1 / Phase 2 |
| Completed | A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective NCT01754987 | Thomas Jefferson University | Phase 1 / Phase 2 |
| Unknown | Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma NCT00752063 | The University of Hong Kong | Phase 2 |